



---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 9, 2007

INTEGRA LIFESCIENCES HOLDINGS  
CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

(State or other Jurisdiction of  
Incorporation)

0-26224

(Commission File Number)

51-0317849

(IRS Employer Identification No.)

311 Enterprise Drive  
Plainsboro, NJ

(Address of Principal Executive Offices)

08536

(Zip Code)

Registrant's telephone number, including area code: (609) 275-0500

**Not Applicable**

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.**

On May 9, 2007, Integra LifeSciences Holdings Corporation posted to the “Investor Relations” portion of its website ([www.Integra-LS.com](http://www.Integra-LS.com)) presentations that included adjusted net income and adjusted diluted earnings per share for prior periods as well as a reconciliation of these measures to GAAP net income and GAAP earnings per diluted share. A copy of the material relating to adjusted net income and adjusted diluted earnings per share is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item.

The information contained in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information contained in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

**ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.**

(d) Exhibits.

<u>Exhibit Number</u>	<u>Description of Exhibit</u>
99.1	Selected Information from Website Presentations

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

**INTEGRA LIFESCIENCES HOLDINGS CORPORATION**

*Date: May 9, 2007*

*By: /s/ Stuart M. Essig \_\_\_\_\_  
Stuart M. Essig  
President and Chief Executive Officer*

---

**Exhibit Index**

Exhibit Number

Description of Exhibit

99.1

Selected Information from Website Presentations

## RECONCILIATION OF REPORTED GAAP EARNINGS PER DILUTED SHARE TO ADJUSTED EARNINGS PER DILUTED SHARE (Q1 06 – Q4 06)





(In thousands, except per share data)

	Q1 06	Q2 06	Q3 06	Q4 06	2006
GAAP net income	\$ 8,705	\$ 7,977	\$ 2,594	\$ 10,131	\$ 29,407
Non-GAAP adjustments:					
Acquisition-related charges	464	3,727	6,999	903	12,093
Facility consolidation, manufacturing transfer and system integration charges	518	199	-	-	717
Employee termination and related costs	213	208	-	693	1,114
Charges associated with convertible debt exchange offer	-	87	1,792	-	1,879
Charges associated with termination of interest rate swap	-	-	1,425	-	1,425
Income tax expense (benefit) related to above adjustments	(309)	(1,171)	(1,757)	(469)	(3,706)
Quarterly adjustment to income tax expense related to significant changes in the year-to-date expected effective income tax rate	-	-	-	1,246	-
Total of non-GAAP adjustments	886	3,050	8,469	2,373	13,522
Adjusted net income	9,591	11,027	11,053	12,504	42,929
Add back of after tax interest expense	813	684	755	2	2,254
Adjusted net income for diluted earnings per share	\$ 10,404	\$ 11,711	\$ 11,808	\$ 12,506	\$ 45,183
Weighted average common shares outstanding for diluted net income per share	33,828	33,804	29,863	30,084	32,747
Assumed conversion of convertible notes	-	-	3,381	-	-
Adjusted weighted average common shares outstanding for adjusted diluted net income per share	33,828	33,804	33,244	30,084	32,747
GAAP diluted net income per share	\$ 0.28	\$ 0.26	\$ 0.09	\$ 0.34	\$ 0.97
Non-GAAP adjustments detailed above (per share)	\$ 0.03	\$ 0.09	\$ 0.27	\$ 0.08	\$ 0.41
Adjusted diluted net income per share	\$ 0.31	\$ 0.35	\$ 0.36	\$ 0.42	\$ 1.38



# ADJUSTED DILUTED EARNINGS PER SHARE (Q1 05 – Q1 07)




**A reconciliation of reported GAAP EPS to Adjusted Diluted EPS is provided at the end of this presentation**

The adjusted diluted earnings per share amounts presented above for Q1 –Q4 2006 are different from those previously reported, as prior amounts were adjusted for the effects of FAS 123R.

---

# Adjusted Diluted Earnings Per Share



The adjusted diluted earnings per share amounts presented above for Q1 –Q4 2006 are different from those previously reported, as prior amounts were adjusted for the effects of FAS 123R.

A description and discussion of the purpose and uses for Adjusted Diluted EPS is provided in Integra's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 9, 2007. This Current Report on Form 8-K is available on the "SEC Filings" page of the Investor Relations Section of our website at [www.Integra-LS.com](http://www.Integra-LS.com). A reconciliation of reported GAAP EPS to Adjusted Diluted EPS is available in the Quarterly Financial Summary presentation on the "Presentations and Webcasts" page of the Investor Relations section of our website.